MircroRNA-145 Attenuates Cardiac Fibrosis Via Regulating Mitogen-Activated Protein Kinase Kinase Kinase 3.
Mice
Animals
Myocardium
/ pathology
MicroRNAs
/ genetics
MAP Kinase Kinase Kinase 3
/ metabolism
Myocardial Infarction
/ pathology
Heart Failure
/ metabolism
Collagen
/ metabolism
Transforming Growth Factor beta
/ metabolism
Fibrosis
Angiotensin II
/ metabolism
Transforming Growth Factor beta1
/ metabolism
Cardiac fibrosis
Mitogen-activated protein kinase kinase kinase 3
Myocardial infarction
microRNA-145
Journal
Cardiovascular drugs and therapy
ISSN: 1573-7241
Titre abrégé: Cardiovasc Drugs Ther
Pays: United States
ID NLM: 8712220
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
accepted:
29
12
2021
medline:
3
8
2023
pubmed:
14
4
2022
entrez:
13
4
2022
Statut:
ppublish
Résumé
This study aimed to explore the effect of microRNA (miR)-145 on cardiac fibrosis in heart failure mice and its target. Experiments were carried out in mice receiving left coronary artery ligation, transverse aortic constriction (TAC), or angiotensin (Ang) II to trigger heart failure, and in cardiac fibroblasts (CFs) with Ang II-induced fibrosis. The miR-145 levels were decreased in the mice hearts of heart failure induced by myocardial infarction (MI), TAC or Ang II infusion, and in the Ang II-treated CFs. The impaired cardiac function was ameliorated by miR-145 agomiR in MI mice. The increased fibrosis and the levels of collagen I, collagen III, and transforming growth factor-beta (TGF-β) in MI mice were inhibited by miR-145 agomiR or miR-145 transgene (TG). The agomiR of miR-145 also attenuated the increases of collagen I, collagen III, and TGF-β in Ang II-treated CFs. Bioinformatics analysis and luciferase reporter assays indicated that mitogen-activated protein kinase kinase kinase 3 (MAP3K3) was a direct target gene of miR-145. MAP3K3 expression was suppressed by MiR-145 in CFs, while the MAP3K3 over-expression reversed the inhibiting effects of miR-145 agomiR on the Ang II-induced increases of collagen I, collagen III, and TGF-β in CFs. These results indicated that miR-145 upregulation could improve cardiac dysfunction and cardiac fibrosis by inhibiting MAP3K3 in heart failure. Thus, upregulating miR-145 or blocking MAP3K3 can be used to treat heart failure and cardiac fibrosis.
Identifiants
pubmed: 35416554
doi: 10.1007/s10557-021-07312-w
pii: 10.1007/s10557-021-07312-w
doi:
Substances chimiques
MicroRNAs
0
MAP Kinase Kinase Kinase 3
EC 2.7.11.25
Collagen
9007-34-5
Transforming Growth Factor beta
0
Angiotensin II
11128-99-7
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-665Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Park GS, An MK, Yoon JH, et al. Botulinum toxin type a suppresses pro-fibrotic effects via the JNK signaling pathway in hypertrophic scar fibroblasts. Arch Dermatol Res. 2019;311:807–14.
doi: 10.1007/s00403-019-01975-0
pubmed: 31501922
Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5:15.
doi: 10.1186/1755-1536-5-15
pubmed: 22943504
pmcid: 3464725
Kwak HB. Aging, exercise, and extracellular matrix in the heart. J Exerc Rehabil. 2013;9:338–47.
doi: 10.12965/jer.130049
pubmed: 24278882
pmcid: 3836529
Flevaris P, Vaughan D. The role of plasminogen activator inhibitor Type-1 in fibrosis. Semin Thromb Hemost. 2017;43:169–77.
doi: 10.1055/s-0036-1586228
pubmed: 27556351
Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H. Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-beta signaling. Front Cardiovasc Med. 2020;7:34.
doi: 10.3389/fcvm.2020.00034
pubmed: 32211422
pmcid: 7075814
Hanna A, Humeres C, Frangogiannis NG. The role of Smad signaling cascades in cardiac fibrosis. Cell Signal. 2021;77:109826.
doi: 10.1016/j.cellsig.2020.109826
pubmed: 33160018
To KKW, Fong W, Tong CWS, Wu M, Yan W, Cho WCS. Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments. Expert Opin Drug Discov. 2020;15:63–83.
doi: 10.1080/17460441.2020.1690449
pubmed: 31739699
Zhang B, Tian L, Xie J, Chen G, Wang F. Targeting miRNAs by natural products: a new way for cancer therapy. Biomed Pharmacother. 2020;130:110546.
doi: 10.1016/j.biopha.2020.110546
pubmed: 32721631
Arcidiacono B, Chiefari E, Foryst-Ludwig A, et al. Obesity-related hypoxia via miR-128 decreases insulin-receptor expression in human and mouse adipose tissue promoting systemic insulin resistance. EBioMedicine. 2020;59:102912.
doi: 10.1016/j.ebiom.2020.102912
pubmed: 32739259
pmcid: 7502675
Cakmak HA, Demir M. MicroRNA and cardiovascular diseases. Balkan Med J. 2020;37:60–71.
pubmed: 32018347
pmcid: 7094181
Kura B, Szeiffova Bacova B, Kalocayova B, Sykora M, Slezak J. Oxidative stress-responsive microRNAs in heart injury. Int J Mol Sci. 2020;21:358.
doi: 10.3390/ijms21010358
pubmed: 31948131
pmcid: 6981696
Huang S, Zhang L, Song J, et al. Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model. J Cell Physiol. 2019;234:2997–3006.
doi: 10.1002/jcp.27117
pubmed: 30146700
Liu Y, Song JW, Lin JY, Miao R, Zhong JC. Roles of MicroRNA-122 in cardiovascular fibrosis and related diseases. Cardiovasc Toxicol. 2020;20:463–73.
doi: 10.1007/s12012-020-09603-4
pubmed: 32856216
pmcid: 7451782
Yang X, Yu T, Zhang S. MicroRNA-489 suppresses isoproterenol-induced cardiac fibrosis by downregulating histone deacetylase 2. Exp Ther Med. 2020;19:2229–35.
pubmed: 32104288
pmcid: 7027313
Zhang M, Cheng YJ, Sara JD, et al. Circulating MicroRNA-145 is associated with acute myocardial infarction and heart failure. Chin Med J. 2017;130:51–6.
doi: 10.4103/0366-6999.196573
pubmed: 28051023
pmcid: 5221112
Wu J, Huang Q, Li P, et al. MicroRNA-145 promotes the epithelial-mesenchymal transition in peritoneal dialysis-associated fibrosis by suppressing fibroblast growth factor 10. J Biol Chem. 2019;294:15052–67.
doi: 10.1074/jbc.RA119.007404
pubmed: 31431501
pmcid: 6791318
Liu Z, Tao B, Fan S, et al. Over-expression of microRNA-145 drives alterations in beta-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction. Aging (Albany NY). 2020;12:11603–22.
doi: 10.18632/aging.103320
pubmed: 32554856
Xu Z, Sun J, Tong Q, et al. The role of ERK1/2 in the development of diabetic cardiomyopathy. Int J Mol Sci. 2016;17. https://doi.org/10.3390/ijms17122001
Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40.
doi: 10.1038/35065000
pubmed: 11242034
Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532–41.
doi: 10.1111/liv.12633
pubmed: 25040043
Castillero E, Akashi H, Najjar M, et al. Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis. Am J Physiol Heart Circ Physiol. 2020;318:H378–H90.
doi: 10.1152/ajpheart.00302.2019
pubmed: 31886717
Yang Z, Zhang X, Guo N, Li B, Zhao S. Substance P inhibits the collagen synthesis of rat myocardial fibroblasts induced by Ang II. Med Sci Monitor: Int Med J Exp Clin Res. 2016;22:4937–46.
doi: 10.12659/MSM.898454
Yang X, Wang Y, Yan S, et al. Effect of testosterone on the proliferation and collagen synthesis of cardiac fibroblasts induced by angiotensin II in neonatal rat. Bioengineered. 2017;8:14–20.
doi: 10.1080/21655979.2016.1227141
pubmed: 27791460
Wolfien M, Klatt D, Salybekov AA, et al. Hematopoietic stem-cell senescence and myocardial repair - coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT phase 3. EBioMed. 2020;57:102862.
doi: 10.1016/j.ebiom.2020.102862
Wojciechowska A, Braniewska A, Kozar-Kaminska K. MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med. 2017;26:865–74.
doi: 10.17219/acem/62915
pubmed: 29068585
Zhang J, Wei X, Zhang W, Wang F, Li Q. MiR-326 targets MDK to regulate the progression of cardiac hypertrophy through blocking JAK/STAT and MAPK signaling pathways. Eur J Pharmacol. 2020;872:172941.
doi: 10.1016/j.ejphar.2020.172941
pubmed: 31972179
Song JJ, Yang M, Liu Y, et al. MicroRNA-122 aggravates angiotensin II-mediated apoptosis and autophagy imbalance in rat aortic adventitial fibroblasts via the modulation of SIRT6-elabela-ACE2 signaling. Eur J Pharmacol. 2020;883:173374.
doi: 10.1016/j.ejphar.2020.173374
pubmed: 32682786
pmcid: 7364171
Dutka M, Bobinski R, Korbecki J. The relevance of microRNA in post-infarction left ventricular remodelling and heart failure. Heart Fail Rev. 2019;24:575–86.
doi: 10.1007/s10741-019-09770-9
pubmed: 30710255
pmcid: 6560007
Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016;18:457–68.
doi: 10.1002/ejhf.495
pubmed: 26869172
Sun D, Yang F. Metformin improves cardiac function in mice with heart failure after myocardial infarction by regulating mitochondrial energy metabolism. Biochem Biophys Res Commun. 2017;486:329–35.
doi: 10.1016/j.bbrc.2017.03.036
pubmed: 28302481
Adapala RK, Kanugula AK, Paruchuri S, Chilian WM, Thodeti CK. TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation. Basic Res Cardiol. 2020;115:14.
doi: 10.1007/s00395-020-0775-5
pubmed: 31925567
pmcid: 7322630
Polegato BF, Minicucci MF, Azevedo PS, et al. Association between functional variables and heart failure after myocardial infarction in rats. Arq Bras Cardiol. 2016;106:105–12.
pubmed: 26815462
pmcid: 4765008
Wang K, Zhu ZF, Chi RF, et al. The NADPH oxidase inhibitor apocynin improves cardiac sympathetic nerve terminal innervation and function in heart failure. Exp Physiol. 2019;104:1638–49.
doi: 10.1113/EP087552
pubmed: 31475749
Gabisonia K, Prosdocimo G, Aquaro GD, et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature. 2019;569:418–22.
doi: 10.1038/s41586-019-1191-6
pubmed: 31068698
pmcid: 6768803
Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118:1021–40.
doi: 10.1161/CIRCRESAHA.115.306565
pubmed: 26987915
pmcid: 4800485
Cui S, Liu Z, Tao B, et al. miR-145 attenuates cardiac fibrosis through the AKT/GSK-3beta/beta-catenin signaling pathway by directly targeting SOX9 in fibroblasts. J Cell Biochem. 2021;122:209–21.
doi: 10.1002/jcb.29843
pubmed: 32890431
Zhao L, Ni X, Zhao L, et al. MiroRNA-188 acts as tumor suppressor in non-small-cell lung Cancer by targeting MAP3K3. Mol Pharm. 2018;15:1682–9.
doi: 10.1021/acs.molpharmaceut.8b00071
pubmed: 29528232
Zhang L, Zhang Y, Wang S, et al. MiR-212-3p suppresses high-grade serous ovarian cancer progression by directly targeting MAP3K3. Am J Transl Res. 2020;12:875–88.
pubmed: 32269720
pmcid: 7137041
Lv Y, Huang Y, Xu M, et al. The miR-193a-3p-MAP3k3 signaling Axis regulates substrate topography-induced Osteogenesis of bone marrow stem cells. Adv Sci (Weinh). 2020;7:1901412.
doi: 10.1002/advs.201901412
pubmed: 31921551
Yu C, Liu Y, Sun L, et al. Chronic obstructive sleep apnea promotes aortic remodeling in canines through miR-145/Smad3 signaling pathway. Oncotarget. 2017;8:37705–16.
doi: 10.18632/oncotarget.17144
pubmed: 28465478
pmcid: 5514942
Sawant D, Klevenow E, Baeten JT, et al. Generation of transgenic mice that conditionally express microRNA miR-145. Genesis. 2020;58:e23385.
doi: 10.1002/dvg.23385
pubmed: 32648361
pmcid: 7672654